CascellaM, RajnikM, AleemA, et al.Features Evaluation, and Treatment of Coronavirus (COVID-19). 2023. In: StatPearls [Internet]. StatPearls Publishing: Treasure Island (FL); PMID: 32150360.
3.
GordonDE, JangGM, BouhaddouM, et al.A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature, 2020; 583(7816):459–468; doi: 10.1038/s41586-020-2286-9
4.
HackerKA, BrissPA, RichardsonL, et al.COVID-19 and chronic disease: The impact now and in the future. Prev Chronic Dis, 2021; 18:E62; doi:10.5888/pcd18.210086
5.
IsmailH, MarshallVD, PatelM, et al.The impact of the COVID-19 pandemic on medical conditions and medication adherence in people with chronic diseases. J Am Pharm Assoc (2003), 2022; 62(3):834–839.e1; doi: 10.1016/j.japh.2021.11.013
6.
VabretN, BrittonGJ, GruberC, et al.Immunology of COVID-19: Current state of the science. Immunity, 2020; 52(6):910–941; doi: 10.1016/j.immuni.2020.05.002
7.
van de VeerdonkFL, Giamarellos-BourboulisE, PickkersP, et al.A guide to immunotherapy for COVID-19. Nat Med, 2022; 28(1):39–50; doi: 10.1038/s41591-021-01643-9
8.
MatsumuraT, TakanoT, TakahashiY. Immune responses related to the immunogenicity and reactogenicity of COVID-19 mRNA vaccines. Int Immunol, 2023; 35(5):213–220; doi: 10.1093/intimm/dxac064
9.
WhitselLP, AjenikokoF, ChasePJ, et al.Public policy for healthy living: How COVID-19 has changed the landscape. Prog Cardiovasc Dis, 2023; 76:49–56; doi: 10.1016/j.pcad.2023.01.002
10.
Past SARS-CoV-2 infection protection against re-infection: A systematic review and meta-analysis. Lancet, 2023; 401(10379):833–842; doi: 10.1016/S0140-6736(22)02465-5
11.
MöhlendickB, SchönfelderK, BreuckmannK, et al.ACE2 polymorphism and susceptibility for SARS-CoV-2 infection and severity of COVID-19. Pharmacogenet Genomics, 2021; 31(8):165–171; doi: 10.1097/FPC.0000000000000436
12.
ZhengB, YuanM, MaQ, et al.Landscape of SARS-CoV-2 spike protein-interacting cells in human tissues. Int Immunopharmacol, 2021; 95:107567; doi: 10.1016/j.intimp.2021.107567
13.
SamavatiL, UhalBD. ACE2, Much more than just a receptor for SARS-COV-2. Front Cell Infect Microbiol, 2020; 10:317; doi: 10.3389/fcimb.2020.00317. eCollection 2020
14.
NeteaMG, Domínguez-AndrésJ, van de VeerdonkFL, et al.Natural resistance against infections: Focus on COVID-19. Trends Immunol, 2022; 43(2):106–116; doi: 10.1016/j.it.2021.12.001
15.
CocuzzoB, WrenchA, O'MalleyC. Effects of COVID-19 on older adults: Physical, mental, emotional, social, and financial problems seen and unseen. Cureus, 2022; 14(9):e29493; doi: 10.7759/cureus.. eCollection 2022 Sep
16.
MinatoN, HattoriM, HamazakiY. Physiology and pathology of T-cell aging. Int Immunol, 2020; 32(4):223–231; doi: 10.1093/intimm/dxaa006
17.
PintiM, AppayV, CampisiJ, et al.Aging of the immune system: Focus on inflammation and vaccination. Eur J Immunol, 2016; 46(10):2286–2301; doi: 10.1002/eji.201546178
18.
TrougakosIP, TerposE, AlexopoulosH, et al.Adverse effects of COVID-19 mRNA vaccines: The spike hypothesis. Trends Mol Med, 2022; 28(7):542–554; doi: 10.1016/j.molmed.2022.04.007
19.
CosentinoM, MarinoF. The spike hypothesis in vaccine-induced adverse effects: Questions and answers. Trends Mol Med, 2022; 28(10):797–799; doi: 10.1016/j.molmed.2022.07.009
20.
ShimizuJ, SasakiT, KoketsuR, et al.Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcR- and ACE2-positive cells. Sci Rep, 2022; 12(1):15612; doi: 10.1038/s41598-022-19993-w
21.
AugustoDG, MurdoloLD, ChatzileontiadouDSM, et al.A common allele of HLA is associated with asymptomatic SARS-CoV-2 infection. Nature, 2023; 620(7972):128–136; doi: 10.1038/s41586-023-06331-x
22.
WodarzD, MayRM, NowakMA. The role of antigen-independent persistence of memory cytotoxic T lymphocytes. Int Immunol, 2000; 12(4):467–477.
23.
Almendro-VázquezP, Laguna-GoyaR, Paz-ArtalE. Defending against SARS-CoV-2: The T cell perspective. Front Immunol. 2023; 14:1107803.
